T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Ryan Storgard; Kai Rejeski; Miguel-Angel Perales; Adam Goldman; Roni Shouval

doi:10.1001/jamaoncol.2024.0662

T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

JAMA Oncol. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0662. Online ahead of print.

Authors

Ryan Storgard¹, Kai Rejeski^{2

3}, Miguel-Angel Perales^{1

2}, Adam Goldman⁴, Roni Shouval^{1

2}

Affiliations

¹ Department of Medicine, Weill Cornell Medical College, New York, New York.
² Adult Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
⁴ Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.

PMID: 38635228
DOI: 10.1001/jamaoncol.2024.0662

No abstract available

Plain language summary

This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells.